Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 2
1991 3
1992 4
1993 2
1994 3
1995 4
1996 4
1997 4
1998 3
1999 7
2000 5
2001 3
2002 5
2003 6
2004 2
2005 9
2006 8
2007 9
2008 5
2009 12
2010 13
2011 11
2012 15
2013 19
2014 23
2015 28
2016 19
2017 17
2018 24
2019 25
2020 15
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

276 results
Results by year
Filters applied: . Clear all
Page 1
NLRP3 inflammasome activation drives tau pathology.
Ising C, Venegas C, Zhang S, Scheiblich H, Schmidt SV, Vieira-Saecker A, Schwartz S, Albasset S, McManus RM, Tejera D, Griep A, Santarelli F, Brosseron F, Opitz S, Stunden J, Merten M, Kayed R, Golenbock DT, Blum D, Latz E, Buée L, Heneka MT. Ising C, et al. Nature. 2019 Nov;575(7784):669-673. doi: 10.1038/s41586-019-1769-z. Epub 2019 Nov 20. Nature. 2019. PMID: 31748742 Free PMC article.
Current and emerging avenues for Alzheimer's disease drug targets.
Loera-Valencia R, Cedazo-Minguez A, Kenigsberg PA, Page G, Duarte AI, Giusti P, Zusso M, Robert P, Frisoni GB, Cattaneo A, Zille M, Boltze J, Cartier N, Buee L, Johansson G, Winblad B. Loera-Valencia R, et al. J Intern Med. 2019 Oct;286(4):398-437. doi: 10.1111/joim.12959. Epub 2019 Aug 29. J Intern Med. 2019. PMID: 31286586 Free article. Review.
A walk through tau therapeutic strategies.
Jadhav S, Avila J, Schöll M, Kovacs GG, Kövari E, Skrabana R, Evans LD, Kontsekova E, Malawska B, de Silva R, Buee L, Zilka N. Jadhav S, et al. Acta Neuropathol Commun. 2019 Feb 15;7(1):22. doi: 10.1186/s40478-019-0664-z. Acta Neuropathol Commun. 2019. PMID: 30767766 Free PMC article. Review.
Several therapeutic approaches have been proposed, including the inhibition of protein kinases or protein-3-O-(N-acetyl-beta-D-glucosaminyl)-L-serine/threonine Nacetylglucosaminyl hydrolase, the inhibition of tau aggregation, active and passive immunotherapies, and tau sil …
Several therapeutic approaches have been proposed, including the inhibition of protein kinases or protein-3-O-(N-acetyl-beta-D-glucosaminyl) …
Monoaminergic neuropathology in Alzheimer's disease.
Šimić G, Babić Leko M, Wray S, Harrington CR, Delalle I, Jovanov-Milošević N, Bažadona D, Buée L, de Silva R, Di Giovanni G, Wischik CM, Hof PR. Šimić G, et al. Prog Neurobiol. 2017 Apr;151:101-138. doi: 10.1016/j.pneurobio.2016.04.001. Epub 2016 Apr 12. Prog Neurobiol. 2017. PMID: 27084356 Free PMC article. Review.
Dementia Therapy Targeting Tau.
Buee L. Buee L. Adv Exp Med Biol. 2019;1184:407-416. doi: 10.1007/978-981-32-9358-8_30. Adv Exp Med Biol. 2019. PMID: 32096053 Review.
Tau, Diabetes and Insulin.
Gratuze M, Joly-Amado A, Buee L, Vieau D, Blum D. Gratuze M, et al. Adv Exp Med Biol. 2019;1184:259-287. doi: 10.1007/978-981-32-9358-8_21. Adv Exp Med Biol. 2019. PMID: 32096044 Review.
276 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page